Skip to main content
. Author manuscript; available in PMC: 2019 Aug 12.
Published in final edited form as: Neurol Clin. 2018 May;36(2):379–394. doi: 10.1016/j.ncl.2018.01.008

Fig. 3.

Fig. 3.

Flowchart of recommended screening for SCLC in patients with LEMS. CT, computed tomography; FDG, F-fluorodeoxyglucose. (From Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10(12):1103; Reprinted with permission from Elsevier (The Lancet).)